//MBC BioLab’s first company, Alector, is getting ready to go public

MBC BioLab’s first company, Alector, is getting ready to go public

Alector moved into MBC BioLabs on the day we opened our doors, and now just over five years later they have two programs in the clinic, a partnership with AbbVie, and are now are preparing to go public. Alector set terms for its initial public offering, which would value the immuno-neurology company at about $1.4 billion!

Alector is developing therapeutics that harness the body’s immune cells power to target neurodegenerative diseases. The company’s lead drug candidate, AL001, is a therapeutic candidate for frontotemporal dementia carrying a progranulin (PGRN) loss-of-function mutation.

Full Press Release

2019-02-10T20:35:31+00:00